Estrogen Signalling and the Metabolic Syndrome

Targeting the Hepatic Estrogen Receptor Alpha Action

Marko Matic, Galyna Bryzgalova, Hui Gao, Per Antonson, Patricia Humire, Yoko Omoto, Neil Portwood, Camilla Pramfalk, Suad Efendic, Per Olof Berggren, Jan Åke Gustafsson, Karin Dahlman-Wright

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

An increasing body of evidence now links estrogenic signalling with the metabolic syndrome (MS). Despite the beneficial estrogenic effects in reversing some of the MS symptoms, the underlying mechanisms remain largely undiscovered. We have previously shown that total estrogen receptor alpha (ERα) knockout (KO) mice exhibit hepatic insulin resistance. To determine whether liver-selective ablation of ERα recapitulates metabolic phenotypes of ERKO mice we generated a liver-selective ERαKO mouse model, LERKO. We demonstrate that LERKO mice have efficient reduction of ERα selectively within the liver. However, LERKO and wild type control mice do not differ in body weight, and have a comparable hormone profile as well as insulin and glucose response, even when challenged with a high fat diet. Furthermore, LERKO mice display very minor changes in their hepatic transcript profile. Collectively, our findings indicate that hepatic ERα action may not be the responsible factor for the previously identified hepatic insulin resistance in ERαKO mice.

Original languageEnglish
Article numbere57458
JournalPLoS One
Volume8
Issue number2
DOIs
StatePublished - Feb 25 2013
Externally publishedYes

Fingerprint

Estrogen Receptor alpha
metabolic syndrome
estrogens
Estrogens
Liver
liver
Insulin
mice
insulin resistance
Nutrition
Ablation
Insulin Resistance
Fats
Hormones
estrogenic properties
Glucose
High Fat Diet
high fat diet
estrogen receptors
Knockout Mice

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Matic, M., Bryzgalova, G., Gao, H., Antonson, P., Humire, P., Omoto, Y., ... Dahlman-Wright, K. (2013). Estrogen Signalling and the Metabolic Syndrome: Targeting the Hepatic Estrogen Receptor Alpha Action. PLoS One, 8(2), [e57458]. https://doi.org/10.1371/journal.pone.0057458

Estrogen Signalling and the Metabolic Syndrome : Targeting the Hepatic Estrogen Receptor Alpha Action. / Matic, Marko; Bryzgalova, Galyna; Gao, Hui; Antonson, Per; Humire, Patricia; Omoto, Yoko; Portwood, Neil; Pramfalk, Camilla; Efendic, Suad; Berggren, Per Olof; Gustafsson, Jan Åke; Dahlman-Wright, Karin.

In: PLoS One, Vol. 8, No. 2, e57458, 25.02.2013.

Research output: Contribution to journalArticle

Matic, M, Bryzgalova, G, Gao, H, Antonson, P, Humire, P, Omoto, Y, Portwood, N, Pramfalk, C, Efendic, S, Berggren, PO, Gustafsson, JÅ & Dahlman-Wright, K 2013, 'Estrogen Signalling and the Metabolic Syndrome: Targeting the Hepatic Estrogen Receptor Alpha Action', PLoS One, vol. 8, no. 2, e57458. https://doi.org/10.1371/journal.pone.0057458
Matic, Marko ; Bryzgalova, Galyna ; Gao, Hui ; Antonson, Per ; Humire, Patricia ; Omoto, Yoko ; Portwood, Neil ; Pramfalk, Camilla ; Efendic, Suad ; Berggren, Per Olof ; Gustafsson, Jan Åke ; Dahlman-Wright, Karin. / Estrogen Signalling and the Metabolic Syndrome : Targeting the Hepatic Estrogen Receptor Alpha Action. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{25ea9895042f461aa1138ca0af374677,
title = "Estrogen Signalling and the Metabolic Syndrome: Targeting the Hepatic Estrogen Receptor Alpha Action",
abstract = "An increasing body of evidence now links estrogenic signalling with the metabolic syndrome (MS). Despite the beneficial estrogenic effects in reversing some of the MS symptoms, the underlying mechanisms remain largely undiscovered. We have previously shown that total estrogen receptor alpha (ERα) knockout (KO) mice exhibit hepatic insulin resistance. To determine whether liver-selective ablation of ERα recapitulates metabolic phenotypes of ERKO mice we generated a liver-selective ERαKO mouse model, LERKO. We demonstrate that LERKO mice have efficient reduction of ERα selectively within the liver. However, LERKO and wild type control mice do not differ in body weight, and have a comparable hormone profile as well as insulin and glucose response, even when challenged with a high fat diet. Furthermore, LERKO mice display very minor changes in their hepatic transcript profile. Collectively, our findings indicate that hepatic ERα action may not be the responsible factor for the previously identified hepatic insulin resistance in ERαKO mice.",
author = "Marko Matic and Galyna Bryzgalova and Hui Gao and Per Antonson and Patricia Humire and Yoko Omoto and Neil Portwood and Camilla Pramfalk and Suad Efendic and Berggren, {Per Olof} and Gustafsson, {Jan {\AA}ke} and Karin Dahlman-Wright",
year = "2013",
month = "2",
day = "25",
doi = "10.1371/journal.pone.0057458",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Estrogen Signalling and the Metabolic Syndrome

T2 - Targeting the Hepatic Estrogen Receptor Alpha Action

AU - Matic, Marko

AU - Bryzgalova, Galyna

AU - Gao, Hui

AU - Antonson, Per

AU - Humire, Patricia

AU - Omoto, Yoko

AU - Portwood, Neil

AU - Pramfalk, Camilla

AU - Efendic, Suad

AU - Berggren, Per Olof

AU - Gustafsson, Jan Åke

AU - Dahlman-Wright, Karin

PY - 2013/2/25

Y1 - 2013/2/25

N2 - An increasing body of evidence now links estrogenic signalling with the metabolic syndrome (MS). Despite the beneficial estrogenic effects in reversing some of the MS symptoms, the underlying mechanisms remain largely undiscovered. We have previously shown that total estrogen receptor alpha (ERα) knockout (KO) mice exhibit hepatic insulin resistance. To determine whether liver-selective ablation of ERα recapitulates metabolic phenotypes of ERKO mice we generated a liver-selective ERαKO mouse model, LERKO. We demonstrate that LERKO mice have efficient reduction of ERα selectively within the liver. However, LERKO and wild type control mice do not differ in body weight, and have a comparable hormone profile as well as insulin and glucose response, even when challenged with a high fat diet. Furthermore, LERKO mice display very minor changes in their hepatic transcript profile. Collectively, our findings indicate that hepatic ERα action may not be the responsible factor for the previously identified hepatic insulin resistance in ERαKO mice.

AB - An increasing body of evidence now links estrogenic signalling with the metabolic syndrome (MS). Despite the beneficial estrogenic effects in reversing some of the MS symptoms, the underlying mechanisms remain largely undiscovered. We have previously shown that total estrogen receptor alpha (ERα) knockout (KO) mice exhibit hepatic insulin resistance. To determine whether liver-selective ablation of ERα recapitulates metabolic phenotypes of ERKO mice we generated a liver-selective ERαKO mouse model, LERKO. We demonstrate that LERKO mice have efficient reduction of ERα selectively within the liver. However, LERKO and wild type control mice do not differ in body weight, and have a comparable hormone profile as well as insulin and glucose response, even when challenged with a high fat diet. Furthermore, LERKO mice display very minor changes in their hepatic transcript profile. Collectively, our findings indicate that hepatic ERα action may not be the responsible factor for the previously identified hepatic insulin resistance in ERαKO mice.

UR - http://www.scopus.com/inward/record.url?scp=84874396118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874396118&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0057458

DO - 10.1371/journal.pone.0057458

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e57458

ER -